Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy constant gamma 3 (IGHG3) is the constant region of the heavy chain of IgG3, a subclass of IgG antibodies, which are secreted or membrane-associated glycoproteins produced by B lymphocytes. These antibodies play a pivotal role in the recognition and elimination of antigens as part of humoral immunity. The constant region facilitates effector functions such as complement activation (particularly potent in IgG3) and interaction with Fc receptors on immune cells, thereby linking antigen recognition to immune responses including phagocytosis and cellular cytotoxicity. IGHG3 is not a therapeutic target itself, but is a structural component and biomarker relevant in certain diseases (such as heavy chain disease and autoimmune or infectious conditions), and in rare cases is targeted for enzymatic modification (e.g., by imlifidase in transplant medicine)
Cleavage of IgG3 heavy chains (by imlifidase for antibody reduction)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy constant gamma 3 (IGHG3).